HKSE · 3839.HK
CPBIO Holding Company Limited
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
Loading market information…
OTC · ISCO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
International Stem Cell Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow International Stem Cell Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
$0.25$0.00 (0.0%)
Biomind Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.73% below the high.
$0.30$0.00 (0.0%)
DATATRAK International, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.3% below the high.
$0.75$0.00 (0.0%)
Vaccinex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.06$0.00 (0.0%)
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.19% below the high.
$0.01-$0.00 (-7.69%)
Evofem Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
$0.01$0.00 (0.0%)
NovelStem International Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$0.01$0.00 (0.0%)
Biocure Technology Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.71% below the high.
